AI Article Synopsis
- The study aimed to update the effectiveness of various disease-modifying antirheumatic drugs (DMARDs) for treating rheumatoid arthritis (RA) and to help revise the European Alliance of Associations for Rheumatology (EULAR) guidelines from 2022.
- A systematic literature review was conducted, analyzing 8969 articles to ultimately select 47 relevant studies that assessed the efficacy of conventional and biologic DMARDs, as well as strategies like switching or tapering medications.
- Findings indicated that conventional DMARDs combined with short-term glucocorticoids were as effective as biologic DMARDs with methotrexate, and certain therapies, like interleukin-6 inhibitors and Janus kinase inhibitors, showed
Article Abstract
Objectives: To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of rheumatoid arthritis (RA).
Methods: This systematic literature review (SLR) investigated the efficacy of conventional synthetic (cs), biological (b), biosimilar and targeted synthetic (ts)DMARDs in patients with RA. Medline, EMBASE, Cochrane CENTRAL and Web of Science were used to identify all relevant articles published since the previous update in 2019 to 14 January 2022.
Results: Of 8969 search results, 169 articles were selected for detailed review and 47 were finally included. Trials investigated the efficacy of csDMARDs, bDMARDs and tsDMARDs, DMARD switching, tapering and trials investigating different treatment strategies. The compounds investigated were csDMARDs (methotrexate (MTX), leflunomide, sulfasalazine, hydroxychloroquine), bDMARDs (abatacept, adalimumab, certolizumab-pegol, denosumab, etanercept, infliximab, levilimab, olokizumab, opineracept, rituximab, sarilumab, tocilizumab) and tsDMARDs (baricitinib, filgotinib, tofacitinib, upadacitinib). The efficacy of csDMARDs+ short-term glucocorticoids in early RA was confirmed and similar to bDMARD+MTX combination therapy. Interleukin-6 pathway inhibition was effective in trials on olokizumab and levilimab. Janus kinase inhibitor (JAKi) was efficacious in different patient populations. After insufficient response to JAKi, patients could respond to TNFi treatment. Tapering of DMARDs was feasible for a proportion of patients, who were able to taper therapy while remaining in low disease activity or remission.
Conclusion: The results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/ard-2022-223365 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Home Visit Records as a Way of Improving Quality of Care: A Quality Improvement Study.
Cureus
December 2024
Family Medicine, Unidade de Saúde Familiar (USF) Vil'Alva, Unidade Local de Saúde do Médio Ave, Santo Tirso, PRT.
Introduction Home visits are a key component of primary care in Portugal, designed for patients unable to visit medical facilities. However, logistical constraints often lead to incomplete real-time clinical records, impacting care quality and safety. This study aimed to improve the quality of home visit records through structural interventions and a continuous quality improvement approach.
View Article and Find Full Text PDFShifting from axillary dissection to targeted axillary surgery after neoadjuvant treatment: the evolving management of occult breast cancer in a monoinstitutional series of 114 patients.
Breast Cancer Res Treat
January 2025
Division of Breast Surgery, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy.
Purpose: The use of neoadjuvant systemic therapy for primary breast cancer can achieve tumor shrinkage, enabling less invasive surgical treatments, such as breast-conserving surgery instead of mastectomy, and sentinel node biopsy instead of axillary dissection. In recent years, an increasing number of studies have explored the use of primary systemic therapy for occult breast cancer with axillary presentation. These studies suggest that a more conservative approach, involving targeted axillary surgery could be cautiously proposed for occult breast cancer after neoadjuvant chemotherapy in selected patients.
View Article and Find Full Text PDFCommunity impacts of aviation noise: a pilot survey.
J Expo Sci Environ Epidemiol
January 2025
formerly Quiet Communities Inc., Concord, MA, USA.
Background: Aviation noise policy in the United States is decades old and has not kept up with the science on the adverse effects of chronic noise exposure. New aviation noise policies are needed for the 21 century, respecting the lived experience of affected communities. Existing surveys have reported adverse impacts from aviation noise but more information is needed to understand the factors that contribute to those impacts.
View Article and Find Full Text PDFCohort profile: creation of the SAIL MELD-B e-cohort (SMC) and SAIL MELD-B children and young adult e-cohort (SMYC) to investigate the lived experience of the 'burdensomeness' of multimorbidity.
BMJ Open
January 2025
Population Data Science, Faculty of Medicine, Swansea University Medical School, Swansea, UK.
Purpose: We have established the SAIL MELD-B electronic cohort (e-cohort SMC) and the SAIL MELD-B children and Young adults e-cohort (SMYC) as a part of the Multidisciplinary Ecosystem to study Lifecourse Determinants and Prevention of Early-onset Burdensome Multimorbidity (MELD-B) project. Each cohort has been created to investigate and develop a deeper understanding of the lived experience of the 'burdensomeness' of multimorbidity by identifying new clusters of burdensomeness concepts, exploring early life risk factors of multimorbidity and modelling hypothetical prevention scenarios.
Participants: The SMC and SMYC are longitudinal e-cohorts created from routinely collected individual-level population-scale anonymised data sources available within the Secure Anonymised Information Linkage (SAIL) Databank.
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force.
Value Health
October 2024
Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand; Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
Objectives: Health technology assessment (HTA) guidelines are intended to support successful implementation of HTA by enhancing consistency and transparency in concepts, methods, process, and use, thereby enhancing the legitimacy of the decision-making process. This report lays out good practices and practical recommendations for developing or updating HTA guidelines to ensure successful implementation.
Methods: The task force was established in 2022 and comprised experts and academics from various geographical regions, each with substantial experience in developing HTA guidelines for national health policymaking.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!